Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Review of pediatric B-ALL CAR-T therapy identifies RAS mutation outcome predictor
New Test Predicts CAR-T Success in Kids
This narrative review synthesizes observational data from 86 pediatric patients with relapsed or refractory B-cell acute lymphoblastic leuke…
A new test can spot hidden genetic risks before a child starts powerful CAR-T cancer therapy.
Phase III trial compares tisagenlecleucel to standard transplant in relapsed aggressive B-cell NHL
Can a one-time cell therapy beat standard treatment for aggressive lymphoma?
This randomized, open-label, multicenter phase III trial enrolled 322 adults with aggressive B-cell NHL relapsed/refractory within 1 year of…
A major trial compares one-time CAR-T cell therapy against standard chemo and stem cell transplant for aggressive lymphoma that returns quic…